References
- Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43: 3618–3731.
- D’Alonzo GE. Survival in patients with primary pulmonary hyper-tension. Annals of Internal Medicine. 1991;115: 343.
- Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. The New England Journal of Medicine. 2004;351: 1425–1436.
- Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (pros-tacyclin) with conventional therapy for primary pulmonary hypertension. The New England Journal of Medicine. 1996;334: 296–301.
- Chambers DC, Cherikh WS, Harhay MO, Hayes D Jr, Hsich E, Khush KK, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart–lung transplantation Report – 2019; Focus theme: donor and recipient size match. The Journal of Heart and Lung Transplantation. 2019;38: 1042–1055.
- Hoeper MM, McLaughlin VV, Dalaan AMA, Satoh T, Galiè N. Treatment of pulmonary hypertension. The Lancet Respiratory Medicine. 2016;4: 323–336.
- Verleden GM, Glanville AR, Lease ED, Fisher AJ, Calabrese F, Corris PA, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment – a consensus report from the Pulmonary Council of the ISHLT. The Journal of Heart and Lung Transplantation. 2019;38: 493–503.
- Modrykamien A. Anemia post-lung transplantation: mechanisms and approach to diagnosis. Chronic Respiratory Disease. 2010;7: 29–34.
- Lyu DM, Zamora MR. Medical complications of lung transplantation. Proceedings of the American Thoracic Society. 2009;6: 101–107.